Targeted therapy for NSCLC: ALK inhibition

Rachel Pearson; Jill M. Kolesar

doi:10.1177/1078155211417477

Targeted therapy for NSCLC: ALK inhibition

Rachel Pearson, Jill M. Kolesar

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Purpose: The purpose of this review article is to describe the emerging data of ALK receptor tyrosine kinaase inhibitors in ALK mutation positive NSCLC.Summary: ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers. Crizotinib is an oral ATP-competitive selective inhibitor of the ALK and MET tyrosine kinases that inhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. A phase II study demonstrated an overall response rate of 57% (95% CI, 46 to 68), with the most common toxicity grade I fatigue and visual disturbances. Elevations in lever function tests were also reported.Conclusion: The ALK receptor tyrosine kinase inhibitor crizotinib may be an effective therapy in ALK mutated NSCLC and is currently being compared to standard chemotherapy for advanced or metastatic NSCLC.

Original language	English
Pages (from-to)	271-274
Number of pages	4
Journal	Journal of Oncology Pharmacy Practice
Volume	18
Issue number	2
DOIs	https://doi.org/10.1177/1078155211417477
State	Published - Jun 2012

Keywords

ALK mutation
Non-small cell lung cancer
crizotinib

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1078155211417477

Cite this

@article{8898981ca9474f8999a84d2fa152df35,

title = "Targeted therapy for NSCLC: ALK inhibition",

abstract = "Purpose: The purpose of this review article is to describe the emerging data of ALK receptor tyrosine kinaase inhibitors in ALK mutation positive NSCLC.Summary: ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers. Crizotinib is an oral ATP-competitive selective inhibitor of the ALK and MET tyrosine kinases that inhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. A phase II study demonstrated an overall response rate of 57% (95% CI, 46 to 68), with the most common toxicity grade I fatigue and visual disturbances. Elevations in lever function tests were also reported.Conclusion: The ALK receptor tyrosine kinase inhibitor crizotinib may be an effective therapy in ALK mutated NSCLC and is currently being compared to standard chemotherapy for advanced or metastatic NSCLC.",

keywords = "ALK mutation, Non-small cell lung cancer, crizotinib",

author = "Rachel Pearson and Kolesar, {Jill M.}",

year = "2012",

month = jun,

doi = "10.1177/1078155211417477",

language = "English",

volume = "18",

pages = "271--274",

number = "2",

}

TY - JOUR

T1 - Targeted therapy for NSCLC

T2 - ALK inhibition

AU - Pearson, Rachel

AU - Kolesar, Jill M.

PY - 2012/6

Y1 - 2012/6

N2 - Purpose: The purpose of this review article is to describe the emerging data of ALK receptor tyrosine kinaase inhibitors in ALK mutation positive NSCLC.Summary: ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers. Crizotinib is an oral ATP-competitive selective inhibitor of the ALK and MET tyrosine kinases that inhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. A phase II study demonstrated an overall response rate of 57% (95% CI, 46 to 68), with the most common toxicity grade I fatigue and visual disturbances. Elevations in lever function tests were also reported.Conclusion: The ALK receptor tyrosine kinase inhibitor crizotinib may be an effective therapy in ALK mutated NSCLC and is currently being compared to standard chemotherapy for advanced or metastatic NSCLC.

AB - Purpose: The purpose of this review article is to describe the emerging data of ALK receptor tyrosine kinaase inhibitors in ALK mutation positive NSCLC.Summary: ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers. Crizotinib is an oral ATP-competitive selective inhibitor of the ALK and MET tyrosine kinases that inhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. A phase II study demonstrated an overall response rate of 57% (95% CI, 46 to 68), with the most common toxicity grade I fatigue and visual disturbances. Elevations in lever function tests were also reported.Conclusion: The ALK receptor tyrosine kinase inhibitor crizotinib may be an effective therapy in ALK mutated NSCLC and is currently being compared to standard chemotherapy for advanced or metastatic NSCLC.

KW - ALK mutation

KW - Non-small cell lung cancer

KW - crizotinib

UR - http://www.scopus.com/inward/record.url?scp=84867080826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867080826&partnerID=8YFLogxK

U2 - 10.1177/1078155211417477

DO - 10.1177/1078155211417477

M3 - Review article

C2 - 21844131

AN - SCOPUS:84867080826

SN - 1078-1552

VL - 18

SP - 271

EP - 274

JO - Journal of Oncology Pharmacy Practice

JF - Journal of Oncology Pharmacy Practice

IS - 2

ER -

Targeted therapy for NSCLC: ALK inhibition

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this